Arcus Biosciences, Inc.
NYSE: RCUS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Terry J. Rosen
- Employees
- 601
- Headquarters
- Hayward, United States
- IPO year
- 2018
- Market cap
- $2.9B
- Website
- https://arcusbio.com
Loading RCUS…
Loading profile data…Frequently asked questions about RCUS
What does Arcus Biosciences, Inc. (RCUS) do?
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lu...
Where does RCUS trade?
Arcus Biosciences, Inc. (RCUS) trades on the New York Stock Exchange.
What sector is RCUS in?
Arcus Biosciences, Inc. (RCUS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Arcus Biosciences, Inc.?
Terry J. Rosen is the chief executive officer of Arcus Biosciences, Inc. (RCUS).
Where is Arcus Biosciences, Inc. headquartered?
Arcus Biosciences, Inc. is headquartered in United States.
Does RCUS pay a dividend?
Arcus Biosciences, Inc. (RCUS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RCUS go public?
Arcus Biosciences, Inc. (RCUS) completed its initial public offering in 2018.